G Vignir Helgason

List of Publications by Year
in descending order

31	2,382	361045 20	454577 30
papers	citations	h-index	g-index

31	31	31	3747
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting autophagy potentiates tyrosine kinase inhibitorâ€“induced cell death in Philadelphia chromosomeâ€“positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2009, 119, 1109-1123.	3.9	503
2	Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nature Medicine, 2017, 23, 1234-1240.	15.2	382
3	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 2012, 119, 1501-1510.	0.6	359
4	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer, 2020, 20, 158-173.	12.8	181
5	Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 2011, 118, 2035-2043.	0.6	106
6	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 2019, 33, 981-994.	3.3	99
7	ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy, 2016, 12, 936-948.	4.3	84
8	The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors. Stem Cells, 2014, 32, 2324-2337.	1.4	83
9	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Journal of the National Cancer Institute, 2018, 110, 467-478.	3.0	76
10	Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 2013, 98, 1335-1343.	1.7	54
11	Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia, 2022, 36, 1-12.	3.3	54
12	Utilizing Stimulated Raman Scattering Microscopy To Study Intracellular Distribution of Label-Free Ponatinib in Live Cells. Journal of Medicinal Chemistry, 2020, 63, 2028-2034.	2.9	50
13	hsa-mir183/EGR1â€“mediated regulation of E2F1 is required for CML stem/progenitor cell survival. Blood, 2018, 131, 1532-1544.	0.6	40
14	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitorâ€“Sensitive and -Resistant Chronic Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 2289-2300.	3.2	38
15	Folate metabolism: a re-emerging therapeutic target in haematological cancers. Leukemia, 2021, 35, 1539-1551.	3.3	38
16	Do we need more drugs for chronic myeloid leukemia?. Immunological Reviews, 2015, 263, 106-123.	2.8	37
17	Role of autophagy in cancer prevention, development and therapy. Essays in Biochemistry, 2013, 55, 133-151.	2.1	33
18	Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy. Current Cancer Drug Targets, 2013, 13, 724-734.	0.8	32

#	Article	IF	Citations
19	Targeting Chronic Myeloid Leukemia Stem Cells. Current Hematologic Malignancy Reports, 2010, 5, 81-87.	1.2	30
20	ULK1 inhibition promotes oxidative stressâ€“induced differentiation and sensitizes leukemic stem cells to targeted therapy. Science Translational Medicine, 2021, 13, eabd5016.	5.8	26
21	The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought. Frontiers in Cell and Developmental Biology, 2018, 6, 120.	1.8	17
22	Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 2012, 12, 381-392.	1.1	15
23	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. Leukemia, 2020, 34, 640-644.	3.3	12
24	Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia. FEBS Journal, 2019, 286, 1271-1283.	2.2	11
25	Oncogene-Induced Sensitization to Chemotherapy-Induced Death Requires Induction as well as Deregulation of E2F1. Cancer Research, 2010, 70, 4074-4080.	0.4	10
26	Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia. Autophagy, 2022, 18, 1734-1736.	4.3	3
27	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 2009, 37, 206-214.	0.2	2
28	Auto-Commentary on: â€œTargeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cellsâ€• Molecular and Cellular Oncology, 2018, 5, e1403532.	0.3	2
29	Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival. Blood, 2016, 128, 932-932.	0.6	2
30	Targeting autophagy potentiates tyrosine kinase inhibitorâ€“induced cell death in Philadelphia chromosomeâ€“positive cells, including primary CML stem cells. Journal of Clinical Investigation, 2013, 123, 3634-3634.	3.9	2
31	Autophagy in hematopoiesis and leukemogenesis. , 2022, , 125-141.		1